Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

Jenny Xiaoyu Li, Marie Hudson, Carrie Ye, Janet Roberts, Aurore Fifi‐Mah, May Y. Choi, Sabrina Hoa, C. Thomas Appleton, Janet Pope, Nancy Maltez, Lourdes Gonzalez Arreola, A Obrzut, Shahin JamalThe Journal of Rheumatology 2024 · DOI

Abstract

Similar numbers of overall irAEs and severity of Rh-irAEs were observed between older vs younger patients who developed Rh-irAEs after treatment with ICI therapy, suggesting that inflammaging does not play a significant role in Rh-irAEs. Larger studies are needed to explore potential differences in patient phenotypes.

Introduction

Immune Checkpoint Inhibitors (ICIs) have revolutionized oncology by "releasing the brakes" on the immune system to attack tumors. However, this heightened immune activity often leads to immune-related adverse events (irAEs), where the body attacks its own healthy tissues. Rheumatic irAEs (Rh-irAEs), such as inflammatory arthritis or myositis, are particularly common and can cause significant morbidity.

There is a long-standing biological concept known as "inflamm-aging"—the idea that as we age, our immune systems shift toward a state of chronic, low-grade inflammation and "immunosenescence." Researchers hypothesized that this pre-existing inflammatory state might make older patients more susceptible to frequent or severe Rh-irAEs when treated with ICIs. This study investigates whether that clinical intuition holds up in a real-world patient cohort.

Methods

The researchers conducted a prospective cohort study using data from 10 Canadian sites within the CanRIO network. They analyzed 139 patients who developed de novo (new-onset) Rh-irAEs after ICI exposure between 2020 and 2023.

Key methodological features included:

  • Stratification: Patients were divided into a "younger" group (<65 years, n=58) and an "older" group (≥65 years, n=81).
  • Standardized Scoring: Severity was measured using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0, where Grade ≥3 is considered "severe."
  • Statistical Modeling: The team used logistic regression to compare Rh-irAE severity and Poisson regression to compare the total number of different irAEs per patient, adjusting for covariates like sex, cancer type, and therapy duration.

The study utilized the CanRIO prospective cohort, a specialized Canadian database established in 2019 to track cancer patients seen by rheumatologists. Unlike many general oncology datasets, this one specifically excludes patients with pre-existing rheumatic diseases to ensure that the observed events are true side effects of the immunotherapy rather than flares of a prior condition.

Key Insights and Results

The "Inflamm-aging" Disconnect

Despite the biological theory that older immune systems are more "primed" for inflammation, the clinical data showed no significant difference in how older vs. younger patients reacted to ICIs rheumatologically. The "flavor" of the adverse events was remarkably similar across age groups. Inflammatory arthritis (ICI-IA) was the most common manifestation for both, affecting 78% of the younger group and 89% of the older group.

Severity and Frequency

  • Severity: 26% of younger patients vs. 27% of older patients experienced severe (Grade ≥3) Rh-irAEs ($p=0.84$).
  • Frequency: There was no statistically significant difference in the number of irAEs experienced ($p=0.21$), though there was a non-significant trend of older patients being more likely to have three or more distinct irAEs (24% vs 14%).
  • Onset Time: Older patients had a longer median time to the onset of rheumatic symptoms (183 days) compared to younger patients (92 days), though this did not reach statistical significance ($p=0.10$).

Treatment and Continuation

There was no significant difference in how doctors treated these side effects based on age. Both groups received similar rates of prednisone (steroids) and DMARDs (disease-modifying anti-rheumatic drugs). Furthermore, age did not influence whether a patient stayed on their cancer treatment; ICI discontinuation occurred in 26% of the younger group and 19% of the older group ($p=0.6$).

Cancer Type as a Driver

Interestingly, the study found that patients with melanoma had higher total numbers of irAEs compared to other cancer types, regardless of age. This suggests that cancer biology might be a stronger driver of toxicity than patient age.

Discussion and Limitations

The authors acknowledge several limitations to the study. While 139 patients is substantial for a specialized cohort, it may lack the power to detect subtle differences in rarer sub-phenotypes like vasculitis or sarcoid-like reactions. Additionally, the cohort only includes patients referred to rheumatologists, potentially missing patients with very mild symptoms managed solely by oncologists. Finally, using 65 as a binary cutoff might miss nuances in the "very elderly" (e.g., 80+).

Future research is needed to determine if age impacts the long-term persistence of these rheumatic symptoms or if the "inflamm-aging" state affects the tumor's response to the ICI itself, even if it doesn't change the side effect profile.

Conclusion

This study finds that age does not significantly impact the frequency or severity of rheumatic side effects in patients receiving cancer immunotherapy. The results challenge the "inflamm-aging" hypothesis in this context, suggesting that older patients can safely receive these life-saving treatments without an increased risk of debilitating joint or muscle complications. For now, the message to clinicians is clear: age alone should not be a barrier to aggressive cancer immunotherapy.

Summary updated

Abstract

Similar numbers of overall irAEs and severity of Rh-irAEs were observed between older vs younger patients who developed Rh-irAEs after treatment with ICI therapy, suggesting that inflammaging does not play a significant role in Rh-irAEs. Larger studies are needed to explore potential differences in patient phenotypes.
BibTeX
@article{li2024effect,
  author = {Jenny Xiaoyu Li and Marie Hudson and Carrie Ye and Janet Roberts and Aurore Fifi‐Mah and May Y. Choi and Sabrina Hoa and C. Thomas Appleton and Janet Pope and Nancy Maltez and Lourdes Gonzalez Arreola and A Obrzut and Shahin Jamal},
  title = {{Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)}},
  journal = {The Journal of Rheumatology},
  year = {2024},
  doi = {10.3899/jrheum.2024-0603},
}
Figure